<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796171</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2011-000033-36</org_study_id>
    <nct_id>NCT01796171</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma</brief_title>
  <acronym>LYMRIT-37-01</acronym>
  <official_title>A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Nanovector</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Nanovector</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin
      lymphoma. Part A of the study included a phase I dose escalation to define the maximum
      tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa
      part to evaluate safety and preliminary efficacy. Part B of the study will assess the
      efficacy and safety of two different Betalutin/lilotomab dosing regimens in adult patients
      with relapsed rituximab / anti-CD20-refractory follicular lymphoma who have received 2 or
      more prior therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A, Phase I</measure>
    <time_frame>12 weeks</time_frame>
    <description>To define Maximum tolerated dose (MTD) of Betalutin Adverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, Phase IIa</measure>
    <time_frame>3 months - 5 years</time_frame>
    <description>To explore tumour response rates in patients receiving Betalutin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B, Phase IIb</measure>
    <time_frame>3 months - 5 years</time_frame>
    <description>Overall response rate</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">207</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part A, Arm 1: with lilotomab pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Arm 2: without pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Arm 3: with rituximab pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Arm 4: with higher dose lilotomab pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Arm 5: with intermediate dose lilotomab pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100mg/m2 lilotomab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Betalutin, 10 MBq/kg b.w. in escalated doses with 40 mg lilotomab pre-dosing</description>
    <arm_group_label>Part A, Arm 1: with lilotomab pre-dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing</description>
    <arm_group_label>Part A, Arm 2: without pre-dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing</description>
    <arm_group_label>Part A, Arm 3: with rituximab pre-dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses with 100 mg/m2 lilotomab pre-dosing</description>
    <arm_group_label>Part A, Arm 4: with higher dose lilotomab pre-dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Betalutin, 20 MBq/kg b.w. in escalated doses with 60 mg/m2 lilotomab pre-dosing</description>
    <arm_group_label>Part A, Arm 5: with intermediate dose lilotomab pre-dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100 mg/m2 lilotomab</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A:

        Inclusion Criteria:

          -  Histologically confirmed (by WHO classification) relapsed incurable non-Hodgkin B-cell
             lymphoma of following subtypes; follicular grade I-IIIA, marginal zone, small
             lymphocytic, lymphoplasmacytic, mantle cell.

          -  Age ≥ 18 years

          -  A pre-study WHO performance status of 0-1

          -  Life expectancy should be ≥ 3 months

          -  &lt;25% tumour cells in bone marrow biopsy

          -  Measurable disease by radiological methods

        Exclusion Criteria:

          -  Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l

          -  Platelet count ≤ 150 x 109 /l

          -  Total bilirubin ≥ 30 mmol/l

          -  ALP and ALAT ≥ 4x normal level

          -  Creatinine ≥ 115 µmol/l (men), 97 µmol/l (women))

          -  Known CNS involvement of lymphoma

          -  Previous total body irradiation

          -  Known history of HAMA

          -  Chemotherapy or immunotherapy received within the last 4 weeks prior to start of study
             treatment. Pretreatment with rituximab is allowed

          -  Previous hematopoietic stem cell transplantation (autologous and allogenic)

          -  Previous treatment with radioimmunotherapy

          -  Receipt of live, attenuated vaccine within 30 days prior to enrolment

          -  Test positive for hepatitis B (HBsAg and anti-HBc)

          -  A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any
             excipient used in rituximab, HH1 or Betalutin

        Part B:

        Inclusion Criteria:

          -  Histologically confirmed (by WHO classification) relapsed non-Hodgkin B-cell FL
             (follicular grade I-IIIA).

          -  Male or female aged ≥ 18 years.

          -  Received at least 2 prior chemotherapy- or immunotherapy-based regimens. Prior therapy
             must include a rituximab/anti-CD20 agent and alkylating agent. Prior exposure to
             idelalisib or other PI3K inhibitors is also allowed.

          -  Patients must be refractory to the last rituximab/anti-CD20 based treatment, defined
             as no response (no CR or PR) during therapy or a response (CR/PR) lasting less than 6
             months after the completion of a regimen of rituximab/anti-CD20 therapy (including
             occurrence of progressive disease (PD) during rituximab/anti-CD20 maintenance therapy,
             or within 6 months of completion of maintenance therapy). A previous regimen is
             defined as one of the following: at least 2 months of single agent therapy; at least 2
             consecutive cycles of chemotherapy.

          -  WHO performance status of 0-2.

          -  Life expectancy of ≥ 3 months.

          -  Bone marrow tumour infiltration &lt; 25% (in biopsy taken from a site not previously
             irradiated).

          -  Measurable disease by CT: longest diameter (LDi) &gt; 1.5 cm for nodal lesion, LDi &gt; cm
             for extra nodal lesion within 28 days prior to start of treatment.

          -  ANC ≥ 1.5 x 109/L.

          -  Platelet count ≥ 150 x 109/L.

          -  Haemoglobin ≥ 9.0 g/dL.

          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except patients with documented
             Gilbert's syndrome [&lt; 3.0 mg/dL]).

          -  Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or ALP ≤ 2.5 x
             ULN (or ≤ 5.0 x ULN with liver involvement by primary disease).

          -  Adequate renal function as demonstrated by a serum creatinine &lt; 1.5 x ULN.

          -  Negative HAMA test at screening.

          -  Negative test at screening for Hepatitis B (negative HBsAG and anti-HBC), Hepatitis C
             and HIV.

        Exclusion Criteria:

          -  Prior hematopoietic allogenic stem cell transplantation.

          -  Prior autologous stem cell transplantation.

          -  Evidence of histological transformation from FL to DLBCL at time of screening.

          -  Previous total body irradiation.

          -  Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational
             agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at
             doses of ≤ 20 mg/day, topical or inhaled corticosteroids, G-CSF or GM-CSF are
             permitted up to 2 weeks prior to start of study treatment). Note: excludes
             pre-treatment with rituximab as part of this study.

          -  Patients with known or suspected CNS involvement of lymphoma.

          -  History of a previous treated cancer except for the following: adequately treated
             local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ,
             superficial bladder cancer, localised prostate cancer undergoing surveillance or
             surgery, localised breast cancer treated with surgery and radiotherapy but not
             including systemic chemotherapy, other adequately treated Stage 1 or 2 cancer
             currently in CR.

          -  Exposure to another CD37 targeting drug.

          -  A known hypersensitivity to rituximab, lilotomab, Betalutin or murine proteins or any
             excipient used in rituximab, lilotomab, or Betalutin.

          -  Has received a live-attenuated vaccine within 30 days prior to enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arne Kolstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <email>clinicaltrials@nordicnanovector.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>50-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Borås</city>
        <zip>50455</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95.</citation>
    <PMID>23267131</PMID>
  </reference>
  <reference>
    <citation>Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7.</citation>
    <PMID>23256748</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radioimmunotherapy</keyword>
  <keyword>Lu-177</keyword>
  <keyword>Phase I study</keyword>
  <keyword>Phase II study</keyword>
  <keyword>Betalutin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

